Literature DB >> 22226093

Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate.

Frederick R Appelbaum1, Andrea Bacigalupo, Robert Soiffer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22226093      PMCID： PMC3260450          DOI： 10.1016/j.bbmt.2011.11.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  15 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts.

Authors:  P L Weiden; K Doney; R Storb; E D Thomas
Journal:  Transplantation       Date:  1979-04       Impact factor: 4.939

3.  Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

Authors:  Steven Z Pavletic; Shelly L Carter; Nancy A Kernan; Jean Henslee-Downey; Adam M Mendizabal; Esperanza Papadopoulos; Roger Gingrich; James Casper; Saul Yanovich; Daniel Weisdorf
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

Review 4.  Antithymocyte globulin for prevention of graft-versus-host disease.

Authors:  Andrea Bacigalupo
Journal:  Curr Opin Hematol       Date:  2005-11       Impact factor: 3.284

5.  A randomized study of the prevention of acute graft-versus-host disease.

Authors:  N K Ramsay; J H Kersey; L L Robison; P B McGlave; W G Woods; W Krivit; T H Kim; A I Goldman; M E Nesbit
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

6.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

Authors:  A Bacigalupo; T Lamparelli; P Bruzzi; S Guidi; P E Alessandrino; P di Bartolomeo; R Oneto; B Bruno; M Barbanti; N Sacchi; M T Van Lint; A Bosi
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

7.  Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis.

Authors:  P Duggan; K Booth; A Chaudhry; D Stewart; J D Ruether; S Glück; D Morris; C B Brown; B Herbut; M Coppes; R Anderson; J Wolff; M Egeler; S Desai; A R Turner; L Larratt; E Gyonyor; J A Russell
Journal:  Bone Marrow Transplant       Date:  2002-11       Impact factor: 5.483

8.  Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  M Mohty; M Labopin; M L Balère; G Socié; N Milpied; R Tabrizi; N Ifrah; Y Hicheri; N Dhedin; M Michallet; A Buzyn; J-Y Cahn; J-H Bourhis; D Blaise; C Raffoux; H Espérou; I Yakoub-Agha
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

9.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Authors:  Jürgen Finke; Wolfgang A Bethge; Claudia Schmoor; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Gérard Socié
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

Review 10.  Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.

Authors:  Laura Johnston
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020
View more
  5 in total

Review 1.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 2.  Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.

Authors:  Basem M William; Marcos de Lima
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

3.  Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment.

Authors:  Feng Jin; Jin He; Chunhui Jin; Wei Fan; Yanhong Shan; Zhefeng Zhang; Liguang Sun; Zheng Hu; Yong-Guang Yang
Journal:  Cell Mol Immunol       Date:  2015-10-26       Impact factor: 11.530

4.  Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation.

Authors:  Elias Hallack Atta; Danielli Cristina Muniz de Oliveira; Luis Fernando Bouzas; Márcio Nucci; Eliana Abdelhay
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 5.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.